Brassicasterol has been reported for its anticancer activity in prostate cancer, which was attributed to AKT and AR dual-targeting signaling [60], and in bladder cancer through its androgen receptor (AR) antagonist action and AR (androgen receptor) expression-reducing effect in bladder epithelial cells [61]. Here, AKT1 is linked to prostate carcinoma.